 1.  Short title This Act may be cited as the  Small Business FDA User Fee Adjustment Act of 2021 .
 2.  Waiver and reduction of OTC monograph fees for small businesses  (a)  In general Section 744M of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–72 ) is amended— (1)  by redesignating subsections (d) through (h) as subsections (e) through (i), respectively; and  (2)  by inserting after subsection (c) the following:  (d)  Fee waiver and reduction for small businesses  (1)  In general  Beginning with respect to fiscal year 2022:  (A)  The Secretary shall waive the fee under subsection (a)(2) with respect to the first OTC monograph order request that a small business submits to the Secretary for review.   (B)  The Secretary shall reduce the fees that are applicable to a small business under subsections (a)(1) (facility fees) and (a)(2) (OTC monograph order request fees), and not waived under subparagraph (A), to 25 percent of the amount otherwise owed.  (2)  Certification  The Secretary shall require any person who applies for a waiver or reduction of fees under paragraph (1) to certify their qualification for the waiver or reduction. The Secretary shall periodically publish in the Federal Register a list of persons making such certifications.  (3)  Small business defined In this subsection, the term  small business  means an entity that has fewer than 500 employees, including employees of affiliates .  (b)  Conforming change to fee revenue amounts Section 744M(b)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–72(b)(2) ) is amended by striking  For each of the fiscal years 2022 through 2025  and inserting  Subject to subsection (d), for each of the fiscal years 2022 through 2025 . 
